Protocol Ledger

NCT04571645 · Phase III · TERMINATED

Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia

Interventional Phase III clinical trial protocol NCT04571645 sponsored by Jazz Pharmaceuticals in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-04-30 Enrollment: 9 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04571645
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)9 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04571645
Protocol FieldVerified Registry Value
NCT IdentifierNCT04571645
Consolidated Lead SponsorJazz Pharmaceuticals
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment9 participants (ACTUAL)
Registered Start Date2021-04-30
WhyStopped ClassificationInsufficient / Slow Accrual

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04571645
Hospital Research SiteLocationSite Profile
UCI Health and Chao Family Comprehensive Cancer CenterOrange, CAOpen Hospital Dossier ->
Henry Ford Health SystemDetroit, MIOpen Hospital Dossier ->
Huntsman Cancer Institute at University of UtahSalt Lake City, UTOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Jazz Pharmaceuticals across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI